A new report takes the long-term view of Biopharmaceutical M&A.
In the past, studies of Biopharma deal making have shown strong positive effects for targets and negative effects for acquirers. But these studies have focused on measuring value creation from individual deals.
This report from Cass Business School’s Study of Strategic Deals and Corporate Portfolio Management looks at overall programs of activity and performance over longer time periods.
Watch this webinar replay and hear key findings from this report. This presentation also uncovers strategies of the excellent corporate portfolio managers who consistently outperform the market.